glp 1 based therapeutics summit 2nd GLP-1-Based 2025 • Biopharma Asia Experts Say GLP-1 Drugs Have

According to FDA labeling for Wegovy (semaglutide 2.4 mg), patients should be evaluated after 12 weeks at the maintenance dose, and discontinuation considered if less than 5% weight loss has been achieved

AOD-9604 is an analogue of human growth hormone (hGH) 177-191, meaning that it is manmade and similar both structurally and functionally to hGH 2

Storage at microdose volumes When using compounded or multi-dose vial semaglutide for microdosing, storage becomes important because the vial will be used over a longer period (drawing smaller amounts means more doses per vial)

Boosts metabolic rate: Increases metabolic efficiency, supporting faster calorie burning

But remember, reconstituted stability limits actual usability to roughly 30 days per batch